Texas federal judge Mark Pittman will conduct a hearing on Friday to consider whether to allow Pfizer to participate in the redaction and release of
Category: Pharmaceuticals
Novo Nordisk’s Wegovy, hamstrung by Catalent FDA write-up, could correct course by mid-2022: analysts
Worry not, Wegovy fans: There’s reason to believe supply of Novo Nordisk’s obesity med could resume as planned by the middle of the year. That’s
What competition? Vertex touts Trikafta’s competitive edge on back of strong 2021
Vertex finished out 2021 strong, smashing analyst’s sales expectations for the full year. Chalk it up to the company’s entrenched position in cystic fibrosis, where
Lilly, BMS drugs join top TV ad spenders in December as Dupixent stays on top
Sanofi and Regeneron’s immunology blockbuster Dupixent ended the year nabbing the highest TV ad spend for December. Spend over the festive month for the drug
Yet another CDMO investment for Fujifilm, with $100M cell therapy plant buy from Atara
Is there no end to Fujifilm’s spending spree to bolster its manufacturing capacity? On Wednesday, the company revealed it will acquire a cell therapy plant from
Fujifilm’s cell therapy ambitions grow with $100M Atara plant buy
Is there no end to Fujifilm’s spending spree to bolster its manufacturing capacity? Wednesday, the company revealed it will acquire a cell therapy plant from Atara
Cancer screening rates still down 2 years into pandemic, as report calls for a continued push for awareness
Stars like Patti Labelle, Jamie Foxx and rapper Chuck D lent their voices to pharma-backed PSAs last year to keep cancer screenings top of mind
Court ruling on bluebird bio’s gene therapy marketing campaign ‘sparks’ dismay at Roche’s Spark
In a blow to Roche, gene therapy developer bluebird bio can continue to use “spark” in its marketing campaign for sickle cell disease—at least for
BioNTech preps hiring spree at mRNA vaccine plant, boosting workforce by 50%
In just two short years, BioNTech will have more than doubled the size of its workforce at the German biologics facility it bought from Novartis
Immunocore wins FDA nod for first uveal melanoma treatment, also first T-cell receptor therapeutic
Uveal melanoma, an aggressive cancer of the eye, has been a particularly tough nut to crack for scientists trying to find a treatment. But with